Fei Fei

Fei Fei


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JSJie Sun
Jie Sun
FFFei Fei
Fei Fei
MZMingqing Zhang
Mingqing Zhang
LWLi yu Wei
Li yu Wei
XZXipeng Zhang
Xipeng Zhang
SZShiwu Zhang
Shiwu Zhang
The application of circulating, cell-free, methylated Septin9 (mSEPT9) DNA in screening and recurrence monitoring is highly promising. CpG island methylator phenotype (CIMP) is associated with microsatellite instability (MSI). The present study was performed to determine the diagnostic accuracy of mSEPT9 for colorectal cancer (CRC) and to evaluate its utility in CRC screening and recurrence monitoring. For screening and diagnosis of CRC, peripheral mSEPT9 detection and fecal occult blood test (FOBT) were performed in 650 subjects, then the level of CEA, CA19–9 and CA724 was quantified in 173 subjects. Clinicopathological parameters and mismatch repair protein were detected among subjects with CRC. For recurrence monitoring of CRC, the sensitivity of mSEPT9 of 70 subjects was compared with tumor markers and contrast enhanced computed tomography (CECT). Seventy-three percent of CRC patients were mSEPT9-positive at 94.5% specificity, and 17.1% of patients with intestinal polyps and adenoma were mSEPT9-positive at 94.5% specificity, which were higher than FOBT for the screening of CRC. The sensitivity and specificity of mSEPT9 for diagnosis and recurrence monitoring were higher than that of CEA, CA19–9 and CA724. The combined detection of mSEPT9 and CECT enhanced the sensitivity for recurrence monitoring. Pre-therapeutic levels of mSEPT9 were strongly associated with TNM stage, Dukes stages and mismatch repair deficiency (dMMR). mSEPT9 analysis might be popularized as a routine biomarker for CRC screening. The combined detection of mSEPT9 and CECT can play an important role for recurrence monitoring. CIMP was highly associated with the pathological stage of CRC and dMMR.

29 August 2019 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
FFFei Fei
Fei Fei
MZMingqing Zhang
Mingqing Zhang
BLBo Li
Bo Li
LZLizhong Zhao
Lizhong Zhao
HWHui Wang
Hui Wang
SZShiwu Zhang
Shiwu Zhang
We previously reported that polyploid giant cancer cells (PGCCs) exhibit cancer stem cell properties and can generate daughter cells with the epithelial-mesenchymal transition phenotype. This study investigated the role of PGCC formation in the prognostic value of neoadjuvant chemoradiation therapy (nCRT) in locally advanced rectal cancer (LARC). The morphological characteristics were observed in patients with LARC after nCRT. Colorectal cancer cell lines were treated with irradiation or chemotherapeutic drugs, and the metastasis-related proteins were detected. 304 nCRT cases and 301 paired non-nCRT cases were collected for analysis. More PGCCs and morphologic characteristics related to invasion and metastasis appeared in tumor tissue after nCRT. Irradiation or chemicals could induce the formation of PGCCs with daughter cells exhibiting strong migratory, invasive, and proliferation abilities. In patients after nCRT, pathologic complete remission, partial remission, stable disease, and progressive disease were observed in 29 (9.54%), 125 (41.12%), 138 (45.39%), and 12 (3.95%) patients, respectively. Mucinous adenocarcinomas (MCs) occurred more frequently in nCRT than in non-nCRT patients (χ2 = 29.352,P=0.001), and the prognosis in MC patients was worse than that in non-MC patients (χ2 = 24.617,P=0.001). The difference in survival time had statistical significance for 60 days (χ2 = 5.357,P=0.021) and 70 days (χ2 = 18.830,P=0.001) rest interval time. On multivariable analysis, 60 days rest interval, Duke’s stage, and recurrence and/or distant metastasis remained significant predictors of survival. In conclusion, irradiation or chemicals induce the formation of PGCCs and PGCCs produce daughter cells with strong migration and invasion abilities after a long incubation period. Appropriate rest interval (incubation period) is very important for patients with LARC who will receive nCRT.


4 March 2024 in Heliyon
Verified
Journal Article
Open access
ZWZhi Wang
Zhi Wang
JBJin Bian
Jin Bian
JYJiayan Yuan
Jiayan Yuan
SZSunyan Zhao
Sunyan Zhao
SHShijia Huang
Shijia Huang
FFFei Fei
Fei Fei
The controlling nutritional status (CONUT) score is an important tool for predicting the prognosis of colorectal cancer (CRC); however, its effectiveness is relatively insufficient. This study aimed to screen for more effective clinical indicators as supplements to the CONUT scoring system and improve the predictive value of CRC prognosis. Between 2014 and 2020, the clinical information of all CRC patients in our unit was retrospectively collected, and the CONUT scores were calculated based on the levels of serum albumin (ALB), lymphocytes (LC), and total cholesterol. The included patients were divided into the following three groups: normal nutrition (0–1), mild malnutrition (2–4), and moderate-to-severe malnutrition (5–12). The correlations between the CONUT score and baseline characteristics and clinical indicators were evaluated. This study ultimately included 5014 CRC patients. The nutritional status of patients with colon cancer (CC) was worse than that of rectal cancer (RC). The nutritional status was worse in men than in women. The older the patient, the poorer the nutritional status, and the poorer the nutritional status, the longer the hospital stay. In addition, poor nutritional status in patients is indicated by higher values of neutrophils (NE), monocytes (MC), eosinophils (EOS), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), carcinoembryogenic antigen (CEA), and lower values of white blood cells (WBC), basophils (BAS), haemoglobin (HB), total protein (TP), triglycerides (TG), low density lipoprotein (LDL), aspartate transaminase (AST), and blood urea nitrogen (BUN), which was statistically significant (P < 0.05). Indicators that significantly correlated with the CONUT score reflected the immune nutritional status, including WBC (odds ratio [OR] = 0.036, P < 0.001), NE (OR = 30.815, P < 0.001), MC (OR = 41.388, P < 0.001), EOS (OR = 27.577, P < 0.001), BAS (OR = 0.006, P = 0.046), and LDL (OR = 0.319, P < 0.001). Additional variables such as WBC, NE, MC, EOS, BAS, and LDL may be used as supplementary indicators in the CONUT scoring system to more effectively predict the clinical prognosis of CRC patients.


16 July 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
PHPeng Huang
Peng Huang
RWRong Wu
Rong Wu
ZYZhimou Yang
Zhimou Yang
YLYuwei Li
Yuwei Li
FFFei Fei
Fei Fei
YYYongjun Yu
Yongjun Yu
Polyploid giant cancer cells (PGCCs) represent a distinct subpopulation of tumor cells characterized by enlarged or multiple nuclei and aneuploidy. PGCCs are products of genomic instability, possessing cancer stem cell properties and exhibiting significant resistance to radiotherapy and chemotherapy. They can generate highly invasive daughter cells through asymmetric division, exhibiting epithelial-mesenchymal transition characteristics, and facilitating tumor recurrence and metastasis. In vivo, PGCCs with daughter cells in tumor tissue can migrate and infiltrate into the forefront stroma to form tumor budding, which are closely related to solid tumor recurrence, metastasis, and drug resistance. Studies have shown that inhibiting sphingolipid enzyme acid ceramidase or regulating autophagy can reduce the production of PGCCs with daughter cells. Under appropriate induction conditions, PGCCs with daughter cells can be induced to differentiate into benign tissues such as adipocytes, chondrocytes, and osteocytes, inhibiting their malignant proliferation and invasive destruction. This study reviewed the recent research developments regarding PGCCs, mainly explored the endogenous mechanisms of PGCCs formation and their malignant phenotype, as well as the process of tumor budding formation in vivo and potential therapeutic strategies targeting PGCCs. The main novelty of this study lies in exploring the translation of PGCCs basic research into the clinical pathological prognostic role of tumor budding, which can reveal the potential mechanism of PGCCs/tumor budding formation at the molecular level, providing theoretical basis for prognosis assessment, monitoring of recurrence and metastasis risks, as well as improving drug resistance and targeted therapy in cancer patients.